Josiah Hornblower has sold STTK and made no open-market buys since May 2021

Josiah Hornblower is a biotechnology entrepreneur and corporate insider best known as the co‑founder and former chairman of Shattuck Labs, Inc. (NASDAQ: STTK), a clinical‑stage biotech company focused on bi‑functional fusion proteins and immunotherapies for cancer and autoimmune disease.( A graduate of Trinity College (Class of 2000), where he majored in art history, Hornblower began his career in finance in New York City, building a specialty in investments tied to oncology, genetics, and related technologies.( His early work in the sector led to the creation of Pelican Therapeutics with longtime collaborator Taylor Schreiber, which ultimately seeded the formation of Shattuck Labs in 2016.(

At Shattuck Labs, Hornblower initially served in senior leadership roles, including chief executive officer and subsequently chairman and founder, helping guide the company through its scientific build‑out and a successful IPO on Nasdaq that raised more than $200 million from prominent public investors.( He has also been reported as serving as chief financial officer in the company’s early years, reflecting his dual background in finance and biotech company building.( Hornblower later stepped back from day‑to‑day operations to become executive chairman, and in 2021 he stepped down from the board, with George Golumbeski, Ph.D., succeeding him as chairman.( Through these roles, Hornblower has played a central part in establishing Shattuck Labs as an emerging player in immuno‑oncology and autoimmune disease therapeutics.(

Written by Perplexity from public sources.